Cancer
Biosimilars and generics saved NHS £324m last year
August 2, 2018Medical Communications, Sales and Marketing Cancer, NHS, biosimilars, funding, generics
The NHS watchdog, NHS Improvement, has revealed that the British National Health Service saved £324 million last financial year by …
Pfizer notches two EU approvals, including Herceptin biosimilar
August 1, 2018Research and Development, Sales and Marketing Cancer, EMA, EU, Genetech, Herceptin, Pfizer, Trazimera, Xeljanz, biosimilar, breast cancer, pharma
Pfizer is patting itself on the back after securing two new approvals in Europe within 24 hours: Xeljanz (tofacitinib citrate) …
Progenics’ Azedra becomes first FDA-approved treatment for adrenal tumours
July 31, 2018Manufacturing and Production, Sales and Marketing Cancer, FDA, Progenics, adrenal cancer, pharma
The FDA has approved its first-ever drug for rare, unresectable tumours of the adrenal gland with its decision to authorise …
Takeda’s Alunbrig topples Pfizer’s Xalkori in ALK-positive lung cancer
July 27, 2018Medical Communications, Research and Development Alunbrig, Cancer, NSCLC, Pfizer, Takeda, Xalkori, lung cancer, pharma
Takeda has unveiled new Phase 3 data showing that its tyrosine kinase inhibitor (TKI) Alunbrig (brigatinib) not only met its …
HPV vaccine to be given to boys in England
July 25, 2018Research and Development Cancer, HPV, infectious disease, sexually transmitted diseases, vaccines, virus
The government has announced that boys in England aged 12 and 13 will be vaccinated against Human Papilloma Virus (HPV) …
FDA expands Pfizer and Astellas’ Xtandi into castration-resistant prostate cancer
July 16, 2018Sales and Marketing Astellas, Cancer, FDA, Pfizer, US, Xtandi, pharma, prostate cancer
Astellas and Pfizer have revealed that their androgen receptor inhibitor Xtandi (enzalutamide) has received approval from the FDA to expand …
AbbVie and Janssen announce failure of cancer drug Imbruvica in Phase 3 trial
July 12, 2018Research and Development AbbVie, Cancer, FDA, Janssen, approval
AbbVie and Janssen have announced that Imbruvica (ibrutinib) failed to achieve the primary endpoint in a late-stage study assessing its …
NICE approves treatment for rare and deadly childhood cancer
July 11, 2018Sales and Marketing Cancer, NICE, UK, neuroblastoma, pharma
NICE has recommended that monoclonal antibody dinutuximab beta be used in treating high-risk neuroblastoma – a rare and deadly form …
Extended use of breast cancer drug tamoxifen linked to increased endometrial cancer risk
July 9, 2018Research and Development, Sales and Marketing Cancer, breast cancer, endometrial cancer, pharma, tamoxifen
New evidence published in the British Journal of Surgery has indicated a troubling link between long-term use of the breast …
Scotland approves first-line treatment for advanced kidney cancer
July 9, 2018Sales and Marketing Cancer, Scotland, fotivda, rcc, tivozanib
The Scottish Medicines Consortium has approved the use of EUSA Pharma’s Fotivda (tivozanib) as a first-line treatment for people with …
Missouri appeals court overturns $55m J&J verdict
July 6, 2018Medical Communications, Sales and Marketing Cancer, J&J, JJ, Litigation, appeal, pharma
A $55 million verdict against the multinational pharmaceutical company Johnson & Johnson has been overturned by an appeals court in …
Ipsen reveals positive Phase 3 data of Cabometyx in liver cancer
July 5, 2018Research and Development Cabometyx, Cancer, ipsen, liver cancer, pharma
French pharmaceutical company Ipsen has announced that The New England Journal of Medicine has published the results of a Phase …
Roche’s Tecentriq combo gives strong Phase 3 showing in triple negative breast cancer
July 2, 2018Research and Development, Sales and Marketing Cancer, Roche, breast cancer, pharma
Roche has unveiled new Phase 3 data on its immunotherapy drug Tecentriq (atezolizumab) in combination with chemotherapy (Celgene’s Abraxane) as …
AstraZeneca chalks up double Japanese approval in lung and breast cancer
July 2, 2018Sales and Marketing AstraZeneca, Cancer, Imfinzi, NSCLD, breast cancer, lung cancer, lynparza, pharma
It’s a big step forward for AstraZeneca’s global marketing operations as the company announced that two of its products have …
Abbvie and Google’s Calico extend age-related disease partnership to $2.5bn
June 27, 2018Research and Development, Sales and Marketing AbbVie, Cancer, Goggle, calico, pharma
The partnership of Abbvie and Google’s Calico has announced they are to extend their existing 10-year drug discovery and development …
Latest content
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion
